Evidence map›Paper›PMID 37546399›Full record

ArticleFrontiers in oncology2023

Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study.

Marion Tonneau, Kim Phan, Venkata S K Manem, Cecile Low-Kam, Francis Dutil, Suzanne Kazandjian, Davy Vanderweyen, Justin Panasci, Julie Malo, François Coulombe and 13 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Marion TonneauDepartment of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
Kim PhanImagia Canexia Health, Montreal, QC, Canada.
Venkata S K ManemInstitut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
Cecile Low-KamImagia Canexia Health, Montreal, QC, Canada.
Francis DutilImagia Canexia Health, Montreal, QC, Canada.
Suzanne KazandjianDepartment of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
Davy VanderweyenDepartment of Radiology, Centre Hospitalier de Sherbrooke (CHUS), Sherbrooke, QC, Canada.
Justin PanasciDepartment of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
Julie MaloDepartment of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
François CoulombeInstitut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
Andréanne GagnéInstitut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
Arielle ElkriefDepartment of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
Wiam BelkaïdDepartment of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
Lisa Di JorioImagia Canexia Health, Montreal, QC, Canada.
Michele OrainInstitut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
Nicole BouchardDepartment of Oncology, Centre Hospitalier de Sherbrooke (CHUS), Sherbrooke, QC, Canada.
Thierry MuanzaDepartment of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
Frank J RybickiImagia Canexia Health, Montreal, QC, Canada.
Kam KafiImagia Canexia Health, Montreal, QC, Canada.
David HuntsmanImagia Canexia Health, Montreal, QC, Canada.
Philippe JoubertInstitut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
Florent ChandelierImagia Canexia Health, Montreal, QC, Canada.
Bertrand RoutyDepartment of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent developments in artificial intelligence suggest that radiomics may represent a promising non-invasive biomarker to predict response to immune checkpoint inhibitors (ICIs). Nevertheless, validation of radiomics algorithms in independent cohorts remains a challenge due to variations in image acquisition and reconstruction. Using radiomics, we investigated the importance of scan normalization as part of a broader machine learning framework to enable model external generalizability to predict ICI response in non-small cell lung cancer (NSCLC) patients across different centers. Methods: Radiomics features were extracted and compared from 642 advanced NSCLC patients on pre-ICI scans using established open-source PyRadiomics and a proprietary DeepRadiomics deep learning technology. The population was separated into two groups: a discovery cohort of 512 NSCLC patients from three academic centers and a validation cohort that included 130 NSCLC patients from a fourth center. We harmonized images to account for variations in reconstruction kernel, slice thicknesses, and device manufacturers. Multivariable models, evaluated using cross-validation, were used to estimate the predictive value of clinical variables, PD-L1 expression, and PyRadiomics or DeepRadiomics for progression-free survival at 6 months (PFS-6). Results: The best prognostic factor for PFS-6, excluding radiomics features, was obtained with the combination of Clinical + PD-L1 expression (AUC = 0.66 in the discovery and 0.62 in the validation cohort). Without image harmonization, combining Clinical + PyRadiomics or DeepRadiomics delivered an AUC = 0.69 and 0.69, respectively, in the discovery cohort, but dropped to 0.57 and 0.52, in the validation cohort. This lack of generalizability was consistent with observations in principal component analysis clustered by CT scan parameters. Subsequently, image harmonization eliminated these clusters. The combination of Clinical + DeepRadiomics reached an AUC = 0.67 and 0.63 in the discovery and validation cohort, respectively. Conversely, the combination of Clinical + PyRadiomics failed generalizability validations, with AUC = 0.66 and 0.59. Conclusion: We demonstrated that a risk prediction model combining Clinical + DeepRadiomics was generalizable following CT scan harmonization and machine learning generalization methods. These results had similar performances to routine oncology practice using Clinical + PD-L1. This study supports the strong potential of radiomics as a future non-invasive strategy to predict ICI response in advanced NSCLC.

Indexed as

DeeplearningDeepRadiomicsimmunotherapyNSCLCradiomics

Identifiers

PMID37546399
PMCPMC10400292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.